The FDA has granted a priority review for VEGF Trap-Eye, a new drug designed to stop the growth of abnormal vessels in the eye. Trap-Eye is a fusion protein that blocks the growth factors leading to neovascularization in macular degeneration. The priority review sets the decision date at August 20, 2011. Bayer and Regeneron are collaborating on the Trap-Eye treatment for wet AMD. Regeneron has exclusive rights to VEGF Trap-Eye in the US, while Bayer intends to market it outside the US.